Gaucher disease and bone manifestations (Q38265941)

1 September 2017

1 reference

title

Gaucher disease and bone manifestations (English)

1 reference

1 September 2017

1 reference

7

1 reference

1 September 2017

Gemma Marcucci

1

0 references

Jean-Yves Reginster

series ordinal

5

object named as

Jean-Yves Reginster

1 reference

1 September 2017

4

John Kanis

1 reference

1 September 2017

8

Maria Luisa Brandi

1 reference

1 September 2017

Ari Zimran

2

1 reference

1 September 2017

Bruno Bembi

series ordinal

3

1 reference

1 September 2017

Renè Rizzoli

series ordinal

6

1 reference

1 September 2017

language of work or name

English

0 references

publication date

7 November 2014

1 reference

Calcified Tissue International

1 September 2017

1 reference

1 September 2017

95

1 reference

1 September 2017

477-494

1 reference

1 September 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1007/s00223-014-9923-y

1 September 2017

0 references

cites work

Gaucher disease: a comprehensive review

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Gaucher disease: complexity in a "simple" disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Laboratory and genetic evaluation of Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Cathepsin-mediated regulation of autophagy in saposin C deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Glucocerebrosidase mutations in subjects with parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

How I treat Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

An overview on bone manifestations in Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Osteoclasts have multiple roles in bone in addition to bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

The Erlenmeyer flask bone deformity in the skeletal dysplasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

A reappraisal of Gaucher disease-diagnosis and disease management algorithms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Bone marker alterations in patients with type 1 Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Therapeutic goals in the treatment of Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Hyperferritinemia and iron overload in type 1 Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

The 1226G (N370S) Gaucher mutation among patients with Legg-Calve-Perthes disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Treatment of lysosomal storage diseases: recent patents and future strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Hip arthroplasty in patients with Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Randomized, controlled trial of miglustat in Gaucher's disease type 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Bone complications in children with Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Therapeutic approaches to bone pathology in Gaucher disease: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Achievement of therapeutic goals with low-dose imiglucerase in Gaucher disease: a single-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

Bone remodelling at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-014-9923-Y

10.1007/S00223-014-9923-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

0 references

1 reference